The aim of this pilot study was to examine the relationship between clinical response, adverse effects, sertraline (SERT) plasma concentrations and the genetic polymorphism of the serotonin transporter gene-linked polymorphic region (5HTTLPR) in 2 ethnic patient groups. The study involved 45 patients in a clinical trial who received a fixed dose regimen of 50 mg SERT for one week, then a variable-dose regimen for a further 6 weeks for major depressive disorder. At weeks 1 and 6, the following assessments were completed: Hamilton Depression Rating Scale (HDRS), Clinical Global Impression (CGI), drug adverse reaction scale and measurement of plasma SERT levels. Genomic analysis for the long and short allele variants of the 5HTTLPR polymorphism was also carried out. Caucasian subjects had a higher rate of l/l genotype while Chinese subjects had higher frequencies of l/s and s/s genotypes. Comparison of the subjects with the 5HTTLPR s/s genotype and those with the l/l and l/s genotypes found no significant differences in the HDRS scores, CGI scores, response rates, adverse effects and SERT plasma concentrations at week 6.
Introduction
In spite of current advances in the pharmacotherapy of mood disorders, there remains substantial inter-individual and interethnic variability in antidepressant response. Although the determinants of such variations are not completely understood, genetic factors are thought to play a large role. The serotonin transporter (5HTT) is a prime target of action of selective serotonin reuptake inhibitors (SSRIs). Drug transporter systems are subject to functional polymorphisms, which may affect both drug availability and response to medication. The rate of polymorphism of the long and short allele of the serotonin transporter gene (5HTTLPR) located on chromosome 17, varies between ethnic groups. Long (l) and short (s) allele frequencies in Caucasians are 57% and 43%, respectively (Lesch et al., 1996) , while in Koreans the frequencies are 14% and 86% (Lee et al., 2004) .
A number of studies have shown a relationship between the functional polymorphisms of the 5HTTLPR and treatment response to SSRIs (Smeraldi et al., 1998; Pollock et al., 2000; Zanardi et al., 2000 Zanardi et al., , 2001 Arias et al., 2003) . These studies in general found that depressed patients with the long allele genotypes (l/l and l/s) showed a greater response to SSRIs than those with the short allele (s/s) (Smits et al., 2004) . However, divergent results have been found in recent studies in Korean and Japanese depressed subjects (Kim et al., 2000; Yoshida et al., 2002) . This may be due to ethnic differences in the 5HTTLPR polymorphism and/or pharmacogenetics of drug targets (Ng et al., 2004) .
